FDA Follow-On Biologics Guidance Will Have Broad Scope, But Not "Break New Ground"

Acting CDER Director Galson says draft guidance will be out this spring. Scientific principles will cover range of biologics therapies – but scientific and legal obstacles will limit impact to a relative handful of products.